Navigation Links
Exon skipping prevents formation of toxic protein fragments in Huntington's disease

New Rochelle, NY, February 11, 2014An innovative therapeutic strategy for reducing the levels of toxic protein fragments associated with Huntington's disease uses a new approach called exon skipping to remove the disease-causing component of the essential protein, huntingtin. Proof of concept using antisense oligonucleotides to "skip over" the specific exon in a mouse model of Huntington's disease is reported in an article in Nucleic Acid Therapeutics, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. The article, part of a special focus issue on exon skipping, is available on the Nucleic Acid Therapeutics website.

Melvin Evers et al., Leiden University Medical Center, The Netherlands, describe the successful use of antisense oligonucleotides to target the mutated exon that causes Huntington's disease in the article "Preventing Formation of Toxic N-Terminal Huntingtin Fragments Through Antisense Oligonucleotide-Mediated Protein Modification."

"No field of therapeutic development is moving faster, with more imminent clinical translation than the nucleic acid based treatment of central nervous system conditions," says Executive Editor Graham C. Parker, PhD, The Carman and Ann Adams Department of Pediatrics, Wayne State University School of Medicine, Children's Hospital of Michigan, Detroit, MI. "The novel therapeutic strategy outlined in Evers et al. gives us a proof of concept of how a previously intractable condition can be treated by modifying rather than removing the toxic protein."

The special issue also includes the Review article "A Chemical View of Oligonucleotides for Exon Skipping and Related Drug Applications." by Peter Jrver, Liz O'Donovan, and Michael Gait, Medical Research Council, Cambridge, U.K. The authors explore the complex chemistry and design of antisense oligonucleotides used for exon skipping and progress in developing new chemistries to improve their stability and binding.

Annemieke Aartsma-Rus, PhD, Leiden University Medical Center, Guest Editor of the issue, emphasizes the need for scientists, clinicians, patients, regulators, and drug manufacturers to work closely together to develop exon skipping therapeutics, which are currently in clinical trials for neuromuscular disorders such as Duchenne muscular dystrophy and spinal muscular atrophy. These complex drugs and the challenging diseases they are targeting require a collaborative effort, she states in her Editorial "Antisense-Mediated Exon Skipping: Networking to Meet Opportunities and to Overcome Challenges."

Nucleic Acid Therapeutics is under the editorial leadership of Co-Editors-in-Chief Bruce A. Sullenger, PhD, Duke Translational Research Institute, Duke University Medical Center, Durham, NC, and C.A. Stein, MD, PhD, City of Hope National Medical Center, Duarte, CA; and Executive Editor Graham C. Parker, PhD.


Contact: Vicki Cohn
914-740-2100 x2156
Mary Ann Liebert, Inc./Genetic Engineering News

Related medicine news :

1. Skipping Meds May Raise Odds of ER Visits for Certain Medicare Patients
2. Many Americans Skipping Meds to Save Money, CDC Says
3. South Jersey Health and Body Explains the Best Ways to Get Nutrients in Your Body if The as Apposed to Always Skipping Meals
4. Skipping Aspirin Before Artery Procedure May Boost Death Rates
5. Weight-Loss Keys: Food Journals, Eating In, Not Skipping Meals
6. Physical fitness improves survival, prevents some heart attacks
7. Japanese superfood prevents flu infection
8. Get Rid of Herpes System Relieves Symptoms and Prevents Outbreaks
9. Avoiding specific region of brain during whole-brain radiotherapy prevents memory loss
10. Online USA Doctors/Virtual Doctors Creates Comprehensive Female Health Plan That Prevents Premature Death in Postmenopausal Women
11. Device Prevents Oil-Gas-/Well Fires Designed by InventHelp® Client (CCP-336)
Post Your Comments:
Related Image:
Exon skipping prevents formation of toxic protein fragments in Huntington's disease
(Date:10/13/2015)... ... ... Scientists in Seattle and Vancouver compared the diagnostic value of lung fluid cytology ... has just posted an article on the new research. Click here to read ... of British Columbia found that certain genetic alterations were seen just as often in ...
(Date:10/13/2015)... ... October 13, 2015 , ... Tempe Dental Care, a leading Tempe ... and IV sedation dentistry for more than 5 years. A leading cause ... serious and painful if treatment is not timely. , Sedation dentistry ...
(Date:10/13/2015)... (PRWEB) , ... October 13, 2015 , ... Local Gold’s ... Gold’s Gym International Conference on August 26. Berry, who owns and operates Gold's ... for the fastest growing Gold’s Gyms in the United States. A brand leader in ...
(Date:10/13/2015)... ... October 13, 2015 , ... Thermi, an ... newest professional to introduce the latest development, ThermiVa® temperature controlled radiofrequency to the ... professional in Obstetrics and Gynecology and a pioneer in the field of laparoscopy. ...
(Date:10/13/2015)... ... October 13, 2015 , ... In an ongoing effort ... , a Southlake, Texas, child development and pediatric therapy center, is working with ... families about their options for receiving this kind of care for affected children. ...
Breaking Medicine News(10 mins):
(Date:10/13/2015)... Calif. , Oct. 13, 2015  SRI ... up to $100 million over five years by ... (NIAID), part of the National Institutes of Health, ... treat acute or delayed effects of radiation exposure. ... a division of SRI International will provide services, ...
(Date:10/13/2015)... , Oct. 13 2015 ... the addition of the "US & ... 16 Countries (2010-2021)" report to their ... announced the addition of the "US ... - 16 Countries (2010-2021)" report to ...
(Date:10/13/2015)... 13, 2015 anesthesia and respiratory ... billion by 2022, according to a new report by ... to their capability to resolve various environmental and lifestyle ... growth. --> anesthesia and respiratory devices market ... 2022, according to a new report by Grand View ...
Breaking Medicine Technology: